Previous 10 | Next 10 |
home / stock / esalf / esalf news
Start Your Day With a Sparkling Pop! Containing 75 Lemons Worth of Vitamin C and 50% Less Calories! TOKYO, Apr 8, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch its new carbonated beverage Chocola BB Sparkling Kiwi & Lemon Flavor, classified as a Food with Nutrient Function Claims,...
Motion Sickness Solution Now Available in Convenience Stores TOKYO, Apr 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch the mouth freshener Travelmin Support as the first quasi-drug of the Travelmin series which can be purchased even at convenience stores and others in Japan on Monday...
TOKYO, Mar 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that in the 8th meeting of the Data Safety Monitoring Board (DSMB) for the global Phase III clinical studies (MISSION AD) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development c...
TOKYO, Mar 22, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer's disease has been initiated. BAN2401 is being jointly developed by Eisai and B...
TOKYO, Mar 22, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline, including anti-amyloid beta (Abeta) protofibril antibody BAN2401 and oral beta amyloid cleaving enzyme (BACE) inhibito...
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials Cambridge, MA, Mar 21, 2019 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) announced the decision to discontinue the global...
Eisai Co., Ltd. ADR (ESALF) Information Meeting 2019 Conference Call March 08, 2019 02:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer and CEO Hiroyuki Kobayashi - Medical Division Ryohei Yanagi - CFO Ivan Cheung - SVP, President of Neurology Busine...
TOKYO, Mar 7, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that a marketing authorization application has been submitted in Japan for lemborexant, an investigational agent for sleep-wake regulation, seeking approval for use in the treatment of insomnia disorder. This application was...
Contributing Further to Patients With Mycetoma, a Neglected Tropical Disease TOKYO, Feb 27, 2019 - (JCN Newswire) - Eisai Co., Ltd. has entered an agreement to support the international non-governmental organization Association for Aid and Relief, Japan's program to raise awareness of myceto...
TOKYO, Feb 21, 2019 - (JCN Newswire) - AbbVie, a research-based global biopharmaceutical company and Eisai Co., Ltd. announced that they have received approval for an additional indication of HUMIRA (generic name: adalimumab [recombinant], "HUMIRA"), a fully human anti-TNF-alpha monoclonal ant...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...